



Auro Laboratories Limited

314, T.V. Industrial Estate, S.K. Ahire Marg
Worli, Mumbai – 400 030. India
Tel. : + 91 22 6663 5456
Fax : + 91 22 6663 5460
Email : auro@aurolabs.com
Web : www.aurolabs.com
Reg. Off / Mfg. Unit :
K-56, M.I.D.C. Tarapur,
Dist. Palghar, Maharashtra – 401506
CIN No. L33125MH1989PLC051910

Date: February 14, 2025

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

Ref: Security Code No. 530233

Sub: Outcome of the meeting of Board of Directors dated February 14, 2025.

Dear Sir / Madam,

Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting to be held on (i.e. **Friday, February 14, 2025**), has transacted the following business:

1. Consider and approved the Unaudited Financial Results of the Company for the quarter ended December 31, 2024 as recommended by the Audit Committee.

In this regard, we are enclosing herewith:

- Unaudited Financial Results for the quarter ended December 31, 2024.
- Limited Review Report received from the Statutory Auditors of the Company.

2. On recommendation of NRC, Board considered and approved the appointment of CS Priyanka Gupta as Company Secretary and Compliance Officer of the Company and designated as a Key Managerial Personnel w.e.f. February 14, 2025.

Details as required under Regulation 30 of the Listing Regulations read with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 is attached herewith as **Annexure – 1.**

The Meeting of the Board of Directors commenced at 3.00 p.m. and concluded at 4.00 p.m.



Auro Laboratories Limited

314, T.V. Industrial Estate, S.K. Ahire Marg

Worli, Mumbai – 400 030. India

Tel. : + 91 22 6663 5456

Fax : + 91 22 6663 5460

Email : auro@aurolabs.com

Web : www.aurolabs.com

Reg. Off / Mfg. Unit :

K-56, M.I.D.C. Tarapur,

Dist. Palghar, Maharashtra – 401506

CIN No. L33125MH1989PLC051910

The results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in due course.

Kindly take the above on record.

Thanking You,

Yours Faithfully,

For **AURO LABORATORIES LIMITED**



SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN: 00230796

Encl.: A/a

AURO LABORATORIES LIMITED

CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR

DIST. PALGHAR 401506, MAHARASHTRA

Tel.: +91-22-66635456 Email. auro@aurolabs.com Web: www.aurolabs.com

PART-1: STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

Part -I


(Rs. In Lakhs except EPS)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operations	305.47	310.12	1,797.84	1,185.82	4,167.23	5,363.62
2	Other Income	14.09	30.79	42.27	67.03	110.54	160.39
3	Total Income (1 + 2)	319.56	340.91	1,840.11	1,252.85	4,267.77	5,513.91
4	Expenses						
a.	Cost of raw material consumed	118.02	(7.91)	761.61	171.42	2,327.22	2,903.70
b.	Purchase of Stock-in-trade	-	-	-	-	-	-
c.	Changes in inventories of finished goods, work-in-progress and stock in trade	110.36	13.48	204.24	233.45	(111.47)	(247.98)
d.	Employee benefits expense	3.40	106.11	122.11	217.74	301.05	514.38
e.	Finance Cost	24.57	28.23	44.48	77.80	106.06	73.67
f.	Depreciation and amortisation expenses	27.00	27.00	27.00	81.00	81.00	109.24
g.	Other Expenses	29.37	127.13	301.88	316.19	814.42	1,126.43
	Total Expenses (4)	312.75	293.06	1,461.32	1,097.61	3,518.25	4,479.34
5	Profit / (Loss) before exceptional items and tax (3 ± 4)	6.81	47.85	378.79	155.24	749.49	1,034.57
6	Exceptional items	-	-	-	-	-	-
7	Profit / (Loss) before tax (5 ± 6)	6.81	47.85	378.79	155.24	749.49	1,034.57
8	Tax expense						
(a)	Current tax expenses for current year	1.71	12.04	105.38	39.07	208.51	274.08
(b)	MAT credit (where applicable)	-	-	-	-	-	-
(c)	Deferred tax	-	-	-	-	-	(18.73)
9	Profit / (Loss) for the period from continuing operation (7 ± 8)	5.10	35.81	273.41	116.17	540.98	779.21
10	Profit / (Loss) for discontinuing operations	-	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-	-
12	Profit / (Loss) for discontinuing operation (after tax) (10 ± 11)	-	-	-	-	-	-
13	Profit / (Loss) for the period (after tax) (9 ± 12)	5.10	35.81	273.41	116.17	540.98	779.21
14	Other Comprehensive Income						
A.	Items that will not be reclassified subsequently to profit or loss						
(i)	Items that will not be reclassified to profit or loss	5.05	39.81	26.14	5.05	26.14	42.94
(ii)	Income tax relating to items that will not be reclassified to profit or loss	(1.27)	(10.02)	(7.27)	(1.27)	(7.27)	(10.81)
B.	Items that will be reclassified subsequently to profit or loss						
(i)	Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii)	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income / (loss), net of tax (14)	3.78	29.79	18.87	3.78	18.87	32.13
15	Total Comprehensive Income for the period (comprising Profit/(Loss) for the period (after tax) and other comprehensive income (after tax)) (13 ± 14)	8.88	65.60	292.28	119.95	559.85	811.34
16	Paid-up equity share capital (Face value of Rs. 10 each)	623.25	623.25	623.25	623.25	623.25	623.25
17	Other Equity	-	-	-	-	-	3,572.60
18	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares)						
(a)	Basic	0.08	0.57	4.39	1.86	8.68	12.50
(b)	Diluted	0.08	0.57	4.39	1.86	8.68	12.50

Notes on financial results:-

- 1) The above unaudited financial results for the quarter and nine month ended December 31, 2024 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on February 14, 2025.
- 2) The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 3) Limited Review has been carried out by the Statutory Auditors of the Company.
- 4) Figures for the Previous period have been regrouped/reclassified wherever necessary to conform to current period's classifications.

FOR & ON BEHALF OF BOARD OF DIRECTORS
AURO LABORATORIES LIMITED



SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN: 00230796

Place : Mumbai
Date : 14/02/2025